SHINE Technologies, the Janesville, Wis.–based producer of medical radioisotopes, announced that it has submitted a drug master file (DMF) with the U.S. Food and Drug Administration for non-carrier-added (n.c.a.) lutetium-177 chloride, a radiopharmaceutical used for the treatment of cancer.
Bruce Power, Nordion to increase Co-60 production
Bruce Power, the utility in Ontario, Canada, and health-care company Nordion announced that they are working to increase the production of cobalt-60 to meet increasing world market demands....
Cherenkov radiation seen in SHINE’s fusion-driven neutron source
SHINE Technologies, a Wisconsin-based medical isotopes and fusion technology company, announced today that it has demonstrated clearly visible Cherenkov radiation produced by fusion for what...
SHINE to open North America’s largest Lu-177 production facility
Fusion tech company SHINE Technologies announced that it is opening the largest facility in North America dedicated to the production of non-carrier-added lutetium-177, a medical isotope used...
SHINE to provide radiation testing for aerospace and defense industries
Fusion development company SHINE Technologies announced that it will begin offering radiation effects testing in a dedicated facility on the company’s Janesville, Wis., campus later this...
University of Missouri to expand isotope production with new research reactor
The University of Missouri intends to build a new, larger research reactor to produce medical radioisotopes, announcing that it intends to issue a request for qualification/request for...
Source Security Working Group continues advocating for access to radiological sources
One of the biggest challenges in the nuclear community identified by ANS in 2017 is the continuous availability of radioisotopes. Working to meet that challenge is the ANS-led Source Security...
SHINE receives final EIS to operate its Mo-99 production facility
The Nuclear Regulatory Commission has issued the final supplemental environmental impact statement (EIS) for SHINE Technology’s application for a license to operate a medical isotope...
Forward fusion: Building a nuclear future in Wisconsin
In a former farm field just outside the historic town of Janesville in south-central Wisconsin, a large concrete-and-steel building is taking shape. Dubbed the Chrysalis, the building will...
NorthStar completes construction of Mo-99 production facility
NorthStar Medical Radioisotopes has completed construction and all equipment installation at its new facility in Beloit, Wis., to produce the medical radioisotope molybdenum-99 without the use...
.png)
Lu-177 production begins at Canada’s Bruce NPP
An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company), and ITM Isotope Technologies Munich SE (ITM) announced they have begun commercial production of...
